8-KEarnings & ResultsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Financial Results (Mar 22, 2017)

Filed March 22, 2017For Securities:ONCBEIGF

Summary

This Form 8-K filing by BeiGene, Ltd. (ONC) on March 22, 2017, primarily serves to announce their financial results for the fiscal year and fourth quarter ended December 31, 2016. Investors should note that the details of these results are contained within a press release furnished as Exhibit 99.1, which is incorporated by reference into this report. The filing itself does not provide the financial figures directly but points to the press release for those details. Therefore, any in-depth analysis of BeiGene's financial performance, operational achievements, or future outlook based solely on this 8-K would require accessing and reviewing the provided press release.

Key Highlights

  • 1BeiGene, Ltd. (ONC) filed a Form 8-K on March 22, 2017.
  • 2The primary purpose of the filing is to report financial results.
  • 3The results are for the year and three months ended December 31, 2016.
  • 4A press release containing the detailed financial results is furnished as Exhibit 99.1.
  • 5The information is furnished and not deemed 'filed' for certain SEC liability purposes.
  • 6Howard Liang, CFO and Chief Strategy Officer, signed the report.

Frequently Asked Questions